Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches
People with coronavirus disease (COVID-19) might have several risk factors for delirium, which could in turn notably worsen the prognosis. Although pharmacological approaches for delirium are debated, haloperidol and other first-generation antipsychotics are frequently employed, particularly for hyp...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-07-01
|
| Series: | Therapeutic Advances in Psychopharmacology |
| Online Access: | https://doi.org/10.1177/2045125320942703 |